Show simple item record

dc.contributor.authorWagner, Teresa R
dc.contributor.authorOstertag, Elena
dc.contributor.authorKaiser, Philipp D
dc.contributor.authorGramlich, Marius
dc.contributor.authorRuetalo, Natalia
dc.contributor.authorJunker, Daniel
dc.contributor.authorHaering, Julia
dc.contributor.authorTraenkle, Bjoern
dc.contributor.authorBecker, Matthias
dc.contributor.authorDulovic, Alex
dc.contributor.authorSchweizer, Helen
dc.contributor.authorNueske, Stefan
dc.contributor.authorScholz, Armin
dc.contributor.authorZeck, Anne
dc.contributor.authorSchenke-Layland, Katja
dc.contributor.authorNelde, Annika
dc.contributor.authorStrengert, Monika
dc.contributor.authorWalz, Juliane S
dc.contributor.authorZocher, Georg
dc.contributor.authorStehle, Thilo
dc.contributor.authorSchindler, Michael
dc.contributor.authorSchneiderhan-Marra, Nicole
dc.contributor.authorRothbauer, Ulrich
dc.date.accessioned2021-05-11T10:58:57Z
dc.date.available2021-05-11T10:58:57Z
dc.date.issued2021-04-27
dc.identifier.citationEMBO Rep. 2021 May 5;22(5):e52325. doi: 10.15252/embr.202052325. Epub 2021 Apr 27.en_US
dc.identifier.pmid33904225
dc.identifier.doi10.15252/embr.202052325
dc.identifier.urihttp://hdl.handle.net/10033/622863
dc.description.abstractIn light of the COVID-19 pandemic, there is an ongoing need for diagnostic tools to monitor the immune status of large patient cohorts and the effectiveness of vaccination campaigns. Here, we present 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potently inhibit the interaction of RBD with angiotensin-converting enzyme 2 (ACE2) as the major viral docking site. Following detailed epitope mapping and structural analysis, we select two inhibitory Nbs, one of which binds an epitope inside and one of which binds an epitope outside the RBD:ACE2 interface. Based on these, we generate a biparatopic nanobody (bipNb) with viral neutralization efficacy in the picomolar range. Using bipNb as a surrogate, we establish a competitive multiplex binding assay ("NeutrobodyPlex") for detailed analysis of the presence and performance of neutralizing RBD-binding antibodies in serum of convalescent or vaccinated patients. We demonstrate that NeutrobodyPlex enables high-throughput screening and detailed analysis of neutralizing immune responses in infected or vaccinated individuals, to monitor immune status or to guide vaccine design.en_US
dc.language.isoenen_US
dc.publisherEMBO Pressen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectSARS-CoV-2en_US
dc.subjectimmune responseen_US
dc.subjectnanobodiesen_US
dc.subjectneutralizing antibodiesen_US
dc.subjectserological assayen_US
dc.titleNeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies.en_US
dc.typeArticleen_US
dc.identifier.eissn1469-3178
dc.contributor.departmentTWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.en_US
dc.identifier.journalEMBO reportsen_US
dc.source.volume22
dc.source.issue5
dc.source.beginpagee52325
dc.source.endpage
refterms.dateFOA2021-05-11T10:58:58Z
dc.source.journaltitleEMBO reports
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Wagner et al.pdf
Size:
2.084Mb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International